Equities Analysts Offer Predictions for DNLI Q1 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Denali Therapeutics in a research report issued on Friday, February 28th. HC Wainwright analyst A. Fein anticipates that the company will post earnings per share of ($0.69) for the quarter. HC Wainwright currently has a “Buy” rating and a $87.00 target price on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Denali Therapeutics’ Q2 2025 earnings at ($0.69) EPS, Q3 2025 earnings at ($0.70) EPS and Q4 2025 earnings at ($0.71) EPS.

Several other research analysts have also weighed in on the stock. Oppenheimer cut their price objective on shares of Denali Therapeutics from $50.00 to $42.00 and set an “outperform” rating on the stock in a report on Monday. Baird R W raised shares of Denali Therapeutics to a “strong-buy” rating in a research report on Tuesday, January 7th. JPMorgan Chase & Co. dropped their price objective on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating for the company in a research report on Tuesday, January 7th. Robert W. Baird started coverage on Denali Therapeutics in a report on Tuesday, January 7th. They issued an “outperform” rating and a $31.00 price target for the company. Finally, Deutsche Bank Aktiengesellschaft began coverage on Denali Therapeutics in a report on Tuesday, February 11th. They issued a “buy” rating and a $31.00 price target for the company. Two research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $37.77.

Denali Therapeutics Stock Performance

Shares of DNLI opened at $15.20 on Monday. The company has a market capitalization of $2.19 billion, a PE ratio of -5.51 and a beta of 1.43. Denali Therapeutics has a fifty-two week low of $14.56 and a fifty-two week high of $33.33. The stock has a fifty day moving average of $21.29 and a two-hundred day moving average of $24.57.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.08.

Insiders Place Their Bets

In other news, insider Carole Ho sold 12,255 shares of Denali Therapeutics stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $247,796.10. Following the transaction, the insider now directly owns 178,580 shares of the company’s stock, valued at $3,610,887.60. This trade represents a 6.42 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Steve E. Krognes sold 3,339 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $20.81, for a total transaction of $69,484.59. Following the transaction, the director now owns 25,757 shares in the company, valued at approximately $536,003.17. The trade was a 11.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 47,940 shares of company stock worth $973,442 over the last ninety days. Company insiders own 7.90% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of DNLI. Sterling Capital Management LLC boosted its holdings in shares of Denali Therapeutics by 589.9% during the fourth quarter. Sterling Capital Management LLC now owns 1,773 shares of the company’s stock worth $36,000 after purchasing an additional 1,516 shares during the period. Quest Partners LLC acquired a new stake in shares of Denali Therapeutics during the 3rd quarter valued at about $73,000. GF Fund Management CO. LTD. bought a new stake in shares of Denali Therapeutics in the 4th quarter valued at approximately $62,000. Point72 Hong Kong Ltd bought a new position in Denali Therapeutics during the fourth quarter valued at approximately $65,000. Finally, PNC Financial Services Group Inc. lifted its stake in Denali Therapeutics by 30.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company’s stock valued at $77,000 after acquiring an additional 885 shares during the last quarter. 92.92% of the stock is owned by institutional investors and hedge funds.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.